“NOVO Holdings to launch USD 165M impact fund to combat AMR”
“Novo Holdings announced 28 February the launch of an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
The fund will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market”
Source: Novonordiskfondsen
Learn more on AMR? Attend one of our dedicated training courses on AMR
